Recently, the development of effective strategies for enhancing drug delivery to the brain has been a topic of great interest in both clinical and pharmaceutical fields. In this review, we summarize our studies evaluating nose-to-brain delivery of drugs and small interfering ribonucleic acids in combination with cell-penetrating peptide-modified polymer micelles. Our findings show that the use ...

BMS-181885, chemically 3-[[3-[4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl]propyl]-1H-indol-5-yl]-4-methyl-3-cyclobutene-1,2,-dione free base (Figure 1), is a potential antimigraine agent. Similar to sumatriptan, a 5-HT agonist, the pharmacological activity of BMS-181885 is elicited by binding to 5-HT1-like receptors. A strong rationale to develop a 5-HT agonist to treat migraine episodes is becau...

Introduction Catatonia is a complex psychomotor syndrome that often goes unrecognized and, consequently, untreated. Prompt and correct identification of catatonia allows for highly effective treatment prevention possible complications. Benzodiazepines electroconvulsive therapy (ECT) are the most widely studied methods. However, no uniform method has yet been brought forward previous attempts to...

Avian influenza A H5N1 is a virus with pandemic potential. Mucosal vaccines are attractive as they have the potential to block viruses at the site of entry, thereby preventing both disease and further transmission. The intranasal route is safe for the administration of seasonal live-attenuated influenza vaccines, but may be less suitable for administration of pandemic vaccines. Research into no...

Intranasal administration of therapeutic agents offers a noninvasive method of drug delivery that bypasses the blood-brain barrier and directly targets the central nervous system (CNS) and lymph nodes. We examined whether intranasal peptoid CHIR5585, an antagonist of the urokinase plasminogen activator receptor (uPAR), is delivered to the CNS. Peptoids are a novel class of peptide isomers that ...